Thursday, 6 April 2017

Federal appeals court rules Mylan can proceed with generic Angiomax

(Reuters) - A U.S. appeals court ruled that Mylan Inc's proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)